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Abstract
Background: Angiogenesis is a critical early event in inflammatory arthritis, facilitating leukocyte migration into the
synovium resulting in invasion and destruction of articular cartilage and bone. This study investigates the effect of TLR2 on
angiogenesis, EC adhesion and invasion using microvascular endothelial cells and RA whole tissue synovial explants ex-vivo.
Methods: Microvascular endothelial cells (HMVEC) and RA synovial explants ex vivo were cultured with the TLR2 ligand,
Pam3CSK4 (1 mg/ml). Angiopoietin 2 (Ang2), Tie2 and TLR2 expression in RA synovial tissue was assessed by
immunohistology. HMVEC tube formation was assessed using Matrigel matrix assays. Ang2 was measured by ELISA.
ICAM-1 cell surface expression was assessed by flow cytometry. Cell migration was assessed by wound repair scratch assays.
ECM invasion, MMP-2 and -9 expression were assessed using transwell invasion chambers and zymography. To examine if
the angiopoietin/Tie2 signalling pathway mediates TLR2 induced EC tube formation, invasion and migration assays were
performed in the presence of a specific neutralising anti-Tie2mAb (10 ug/ml) and matched IgG isotype control Ab (10 ug/
ml).
Results: Ang2 and Tie2 were localised to RA synovial blood vessels, and TLR2 was localised to RA synovial blood vessels,
sub-lining infiltrates and the lining layer. Pam3CSK4 significantly increased angiogenenic tube formation (p,0.05), and
upregulated Ang2 production in HMVEC (p,0.05) and RA synovial explants (p,0.05). Pam3CSK4 induced cell surface
expression of ICAM-1, from basal level of 149654 (MFI) to 6176103 (p,0.01). TLR-2 activation induced an 8.862.8 fold
increase in cell invasion compared to control (p,0.05). Pam3CSK4 also induced HMVEC cell migration and induced MMP-2
and -9 from RA synovial explants. Neutralisation of the Ang2 receptor, Tie2 significantly inhibited Pam3CSK4-induced EC
tube formation and invasion (p,0.05).
Conclusion: TLR2 activation promotes angiogenesis, cell adhesion and invasion, effects that are in part mediated through
the Tie2 signalling pathway, key mechanisms involved in the pathogenesis of RA.
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Introduction
Rheumatoid Arthritis (RA) is a chronic progressive autoimmune
disease characterised by proliferation of synovial membrane (SM),
which leads to degradation of articular cartilage and subchondral
bone. Angiogenesis is an early event required for pannus
development in RA enabling activated monocytes to enter the
SM via endothelial cells (EC) by active recruitment [1,2]. RA
synoviocytes manifest an abnormal phenotype characterised by
increased proliferation, resistance to apoptosis and invasiveness of
adjacent tissue. This leads to a self perpetuating and persistent
infiltration of immune cells resulting in synoviocyte hyperplasia
which transforms SM into an aggressive, tumour-like tissue -
‘pannus’ which is capable of destroying adjacent articular cartilage
and bone. Pro-inflammatory cytokines, such as TNF-a and IL-1b,
are key mediators of these processes, however, it remains unclear
which mechanisms are involved in the initiation and regulation of
cytokine production and other tissue-destructive mediators [3–5].
Toll-Like receptors (TLRs) have been implicated in the
pathogenesis of RA with studies showing increased TLR2 and
TLR4 expression in the perivascular regions of the joint [6], at the
sites of attachment and invasion into cartilage/bone, and on
synovial macrophages [7]. TLR2 ligand bacterial peptidoglycan
(PG) has been detected in RA synovial fluids [8]. Increased
expression of TLR2 has been demonstrated in collagen induced
arthritis, and TLR2 deficient mice do not develop streptococcal
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cell wall (SCW) induced arthritis [9]. Furthermore, it has been
shown that dominant negative forms of the essential TLR2
adapter molecules MyD88 and MAL/TIRAP ablate pro-inflam-
matory cytokine production in RA synoviocytes demonstrating
that TLR2 and TLR4 signalling pathways are functional in these
cells [10].
Angiogenesis is one of the earliest events in the initiation of
synovial inflammation [1]. Several studies have demonstrated that
angiogenesis is highly dysregulated in RA, which is associated with
increased differential expression of pro-angiogenic factors in
synovial fluid and tissue such as VEGF, Angiopoietin 1/2, PlGF,
PDGF or TGFb1, that can promote either immature or mature
stable vessels [11–18]. More recently studies have suggested that
synovial angiogenesis maybe regulated by TLR2 activation. TLR2
is expressed in SM perivascular regions [19], and in vitro studies
confirm that TLR2 activation induces VEGF/IL-8 expression in
synovial fibroblasts and chondrocytes [20,21], and MMP-9 in
corneal epithelial cells and THP-1 macrophages [22]. The aim of
this study is to examine the effects of TLR2 activation on
angiogenic processes using RA synovial explants and HMVEC
cultures. We demonstrate using RA whole tissue SM explants that
TLR2 activation induces Ang2 and MMP2, 9 expression, critical
factors involved in blood vessel destabilisation and advancement
through the inflamed SM. Furthermore we demonstrate that
TLR2 activation significantly induces angiogenic tube formation,
Ang2, ICAM-1 cell surface expression, EC invasion and
migration, effects that in part inhibited by Tie2 receptor blockade.
These results suggest that TLR2 induced angiogenic processes are
in part mediated through the Tie2 signalling pathway.
Materials and Methods
Arthroscopy and sample collection
RA patients with clinically active inflamed knees prior to
biologic therapy were recruited from rheumatology outpatient
clinics at St. Vincent’s University Hospital. Following approval by
the institutional ethics committee, all patients gave written
informed consent. All treatment was fully compliant with the
Helsinki Declaration. RA synovial biopsies were obtained at
arthroscopy as previously described and were either placed in
cryopreservation embedding media OCT compound (Tissue Tek,
The Netherlands) for histological analysis or established as RA
whole tissue synovial explants cultures established [23].
Immunohistochemistry
7 mm OCT sections were placed on glass slides coated with 2%
3-amino-propyl-triethoxy-silane (Sigma-Aldrich, St. Louis, MO)
and dried overnight at room temperature. Sections were stored at
280uC until required for staining. Tissue sections were allowed to
reach room temperature, fixed in acetone for 10 minutes and air-
dried. Non-specific binding and endogenous peroxidase activity
was blocked using 10% casein and 0.3% H2O2 respectively. A
routine three-stage immunoperoxidase labelling technique incor-
porating avidin-biotin-immunoperoxidase complex (DAKO,
Glostrup, Denmark) was used. The sections were incubated with
primary antibodies against mouse-monoclonal Ang2 (R&D
systems, UK), mouse-monoclonal Tie2 (R&D systems, UK) and
mouse monoclonal anti-TLR2 antibody (kind gift from OPSONA
therapeutics, Ireland) at room temperature for 1 hour. Sections
were also incubated with an appropriate isotype matched mouse
monoclonal antibody as a negative control. Colour was developed
in solution containing diaminobenzadine-tetrahydrochloride (Sig-
ma-Aldrich, St. Louis, MO), 0.5% H2O2 in PBS buffer (pH7.6).
Slides were counterstained with haematoxylin and mounted.
RA ST Explant Culture
To examine the effect of Pam3CSK4 on Angiopoietin 2, MMP-
2 and MMP-9 expression in RA synovial tissue we established an
ex vivo RA synovial tissue explant model, which maintains the
synovial architecture and cell-cell contact, and therefore more
closely reflects the in vivo environment [23]. RA synovial explant
tissue was sectioned into 1 mm cubes in 96 well plates (Falcon,
Franklin Lakes, NJ) in RPMI 1640 supplemented with strepto-
mycin (100 units/ml) and penicillin (100 units/ml) and incubated
with Pam3CSK4 (1 mg/ml) for 24 hours at 37uC in 5% CO2.
Previous studies using RA synovial explants cultured with
Pam3CSK4 (0.2 ug/ml–10 ug/ml) demonstrated maximal pro-
inflammatory effects at a concentration of 1 ug/ml [24].
Supernatants were harvested and assayed for Ang2 by ELISA
and MMP2 and 9 by zymography.
Isolation and Culture of HMVEC
Human microvascular endothelial cells HMVEC (Cat.No CC-
2543) (Clonetics, Lonza, Waterville, Inc), were grown in endothelial
basal medium (EBM) supplemented with 5% FCS, 0.5 ml human
epidermal growth factor (hEGF), 0.5 ml hydrocortisone, 0.5 ml
gentamicin, 0.5 ml bovine brain extract (Clonetics, Lonza, Water-
ville, Inc) and were used for experiments between the passages 3–8.
Matrigel in vitro HMVEC tube formation assay
Matrigel (Becton Dickenson) basement membrane matrix was
used to examine HMVEC tube formation in response to
Pam3CSK4. Matrigel (50 ml) was plated in 96 well culture plates
slides and allowed to polymerise at 37uC in 5% CO2 humidified
for 30 mins. HMVEC were removed from culture, trypsinised,
and resuspended at 46104 cells/ml in EBM medium containing
2% FCS (Clonetics). Four hundred microlitres of cell suspension
was added to each chamber, followed by addition of Pam3CSK4
(1 mg/ml) and incubated for 24 h at 37uC in 5% CO2.
Endothelial cell tube formation was examined using phase
contrast microscopy and photographed. A connecting branch
between two discrete EC was counted as one tube and required a
consistent intensity and thickness as previously described [23].
The tube analysis was determined from 5 sequential high
powered fields (Magnification610) focusing on the surface of
the matrigel. To assess the effect of TLR2 blockade cells were
incubated with. To assess if the angiopoietin/Tie2 signalling
pathway mediates Pam3CSK4 induced angiogenesis, experi-
ments were also performed in the presence of a specific mouse
anti-Tie2 mAb (10 ug/ml) and a isotype matched IgG control
mAb (10 ug/ml).
Angiopoeitin2 ELISA
Angiopoietin2 was measured by specific Quantikine ELISA as
per manufacturer’s instructions (R&D systems UK). ELISA
standards ranged from 78–5000 pg/ml. The absorbance was
measured at 450 nm.
Flow cytometric analysis of ICAM-1 on HDEC
HMVEC were plated to a cell count of 56104 in 12 well
plates (Falcon), and allowed to grow to confluence. HMVEC
were incubated in serum reduced EBM for 24 hours (1%FCS)
and then incubated for a further 24 hrs with Pam3CSK4 (1 mg/
ml). Cells were then harvested with a cell scraper and
transferred to fluorescence-activated cell sorting tubes (Becton
Dickinson). Cells were then washed and incubated with an
optimal concentration of phycoerythrin-conjugated monoclonal
mouse anti-ICAM-1 and isotype-matched control (Becton
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Dickinson) for 30 mins at 4uC. Samples were then washed twice
with 1% PBA, and fixed in 1% PFA. ICAM cell surface
expression was quantified using a FACScan flow cytometer
(Becton Dickinson) using Lysis II software. Further experiments
examined the effect of Pam3CSK4 induced ICAM-1, in the
presence of anti-Tie2 mAb (10 ug/ml) or a isotype matched IgG
control mAb (10 ug/ml).
Transwell Invasion Assay
Biocoat Matrigel Invasion Chambers (Becton Dickinson, UK)
were used to assess endothelial cell migration in response to
Pam3CSK4. Cells were seeded at a density of 2.56104 per well in
the migration chamber on 8 mm membranes pre-coated with
matrigel. EGM containing Pam3CSK4 (1 mg/ml) was placed in
the lower well of the chamber. Cells were allowed to migrate for
24 hours in EBM medium containing 1% FCS. Non-migrating
HMVECs were removed from the upper surface by gentle
scrubbing. Migrating cells attached to the lower membrane were
fixed with 1% glutaraldehyde and stained with 0.1% crystal violet.
To assess the average number of migrating cells, cells were
counted in five random high power fields (hpf). To examine if the
angiopoeitin/Tie2 signalling pathway mediates Pam3CSK4
induced cell invasion, experiments were performed in the presence
of a anti-Tie2 (10 ug/ml) neutralising mAb or isotype matched
IgG control mAb (10 ug/ml)
Wound repair assays
HMVEC were seeded onto 48 well plates and allowed to come
to confluence. A single scratch wound was induced through the
middle of each well with a sterile pipette tip. Cells were
subsequently stimulated for 24 hrs with Pam3CSK (1 mg/ml).
HMVEC migration across the wound margins from 12–24 hrs
was assessed and photographed.
Zymography
Cultured supernatants from RA synovial explants incubated
with Pam3CSK4 were separated by electrophoresis under
nonreducing conditions by SDS-PAGE in 10% polyacrlyamide
gels copolymerised with 1% gelatine. Gels were vigorously washed
twice for 25 minutes in 2.5% Triton X-100 to remove SDS, rinsed
for 25 minutes in dH2O, then incubated overnight in 50 mM Tris,
50 mM NaCl, 10 mM CaCl2, pH 7.5 at 37uC. Following
incubation gels were rinsed for 5 minutes in dH2O before addition
of Coomassie blue stain (30% Isopropanol, 10% Acetic Acid,
0.25 mg/ml Brilliant Blue R) for 10 mins. Gels were visualised
using the UVP Bioimaging AutoChemi system (UVP, Cambridge,
UK).
Statistical Analysis
SPSS15 system for windows was used for statistical analysis.
Non-parametric Wilcoxon Signed Rank test for related samples
Figure 1. TLR2 activation induces EC tube formation and Ang2 expression. Human dermal microvascular endothelial cell tubule formation
on matrigel matrix following stimulation with Pam3CSK4 (1 ug/ml). (A) Representative image of baseline tube formation (left panel) and tube
formation following stimulation with Pam3CSK4 (right panel). (B) Quantitative analysis of the number of connecting branches at baseline and in
response to Pam3CSK4. The tube analysis was determined from 5 sequential fields (Magnification640) focussing on the surface of the matrigel (n = 4).
(C–D) The effect of Pam3CSK4 on angiopoietin-2 expression in HMVEC (n = 4) and RA synovial explants (n = 6). Data represented as the mean+/2sem.
*p,0.05 significantly different from baseline. (E) Ang2, Tie2 and TLR2 expression in RA synovial tissue sections.
doi:10.1371/journal.pone.0023540.g001
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was used for analysis of RA synovial explant cultures. Parametric
student t-tests were used for analysis of HMVEC data. P values less
than 0.05 were considered significant.
Results
Pam3CSK4 induces in vitro angiogenesis
Induction of HMVEC tube formation on Matrigel matrices plated
in 96-well culture plates was assessed following stimulation with
Pam3CYSK4 (1 ug/ml). Tube like structures formed after 24 hrs
incubation. Figure 1A shows representative images of increased tube
formation following Pam3CSK4 stimulation as demonstrated by an
increase in the number of connecting branch between two endothelial
cells. Figure 1B graphically illustrates tube formation quantification,
demonstrating significant induction in response to Pam3CSK4
(p,0.05). To determine if Pam3CSK4 directly induces growth factor
secretion in inflammatory cells, the expression of Ang2 in response to
stimulation by Pam3CSK4 in HMVEC and in the ex-vivo RA
synovial explants cultures was assessed. Pam3CSK4 significantly
increased Ang2 expression in HMVEC (Figure 1C) and in the ex-vivo
RA synovial explants (Figure 1D) (all p,0.05). To demonstrate
expression of Ang2, its receptor Tie2 and TLR2 in RA synovial tissue
sections, immunohistochemical analysis was performed. Ang2 and
Tie2 were localised to the blood vessels and to a lesser extent the
lining layer. Figure 1E shows representative images of strong blood
vessel expression for Ang2 and Tie2 in RA synovial tissue sections.
TLR2 expression was localised to the blood vessels, sub-lining
infiltrates and to the lining layer (Figure 1E).
Pam3CSK4 induces ICAM-1 on HDEC
To assess whether Pam3CSK4 can induce adhesion molecules
in HMVEC, we assessed ICAM-1 cell surface expression using
FACS analysis. Figure 2A shows a representative histogram
demonstrating increased cell surface expression of ICAM in
response to Pam3CSK4 compared to basal or control IgG.
Pam3CSK4 stimulation significantly increased ICAM-1 expres-
sion from an MFI intensity of 149654 to 6176103 cells, (Fig. 2A)
(p,0.05) following 24 hrs stimulation.
Pam3CSK4 induces EC invasion and migration
Angiogenesis and EC activation are essential steps in the
progression of RA, therefore to further assess the potential role of
TLR-2 activation in inducing these processes, the effect of
Pam3CSK4 on HMVEC cell invasion and migration was assessed
using transwell matrigelTM invasion chambers, wound repair
assays and zymography. HMVEC were incubated with Pam3-
CYSK (1 ug/ml) for 24 hrs where cells migrated through a 8 mm
membranes pre-coated with matrigel. Following incubation, cells
were fixed and stained with crystal violet. Figure 3A shows
representative images of increased HMVEC invasion under basal
condition where a minimal number of stained EC were observed
compared to Pam3CSK4 stimulated cells where a significant
increase in the number of invading ECs is demonstrated. HMVEC
invasion quantification was significantly induced by Pam3CSK4
(1 mg/ml) where cell invasion increased 8.862.8 fold compared to
control (Figure 3B). To examine the effect of Pam3CYSK4 on
HMVEC migration wound repair assays were performed. A
wound was created through the middle of each well, and cells were
cultured with Pam3CYSK4 from 12–24 hrs. Migration across the
wound margin and repopulation of ECs was assessed. Figure 3C
shows a clear wound under basal condition, where minimal
migration of cells across the wound margin was observed. In
contrast Pam3CSK4 induced cell migration across the wound
margins resulting in almost complete closure of the wound. Finally
Figure 2. TLR2 activation induces ICAM-1 cell surface expression HMVEC. Human dermal microvascular endothelial cells were stimulated
with Pam3CSK4 (1 ug/ml) and expression of ICAM-1 was detected by flow cytometric analysis. (A) Representative flow cytometry histogram
demonstrating induced ICAM-1 expression on HMVEC following stimulation with Pam3CSK4 (black line) compared to basal (grey line). B.
Quantification of ICAM-1 expression following incubation with Pam3CSK4. Data represented as mean fluorescent intensity (mean6sem, n = 4).
* p,0.05 significantly different from unstimulated.
doi:10.1371/journal.pone.0023540.g002
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using gelatin zymography we examined if Pam3CSK4 (200 ng/
ml–1 ug/ml) induced MMP-2 and -9 expression, which are key
metalloproteinases involved in angiogenesis and blood vessel
invasion through the extracellular matrix. Figure 3D shows
representative zymography gel images demonstrating that
Pam3CSK4 at 1 ug/ml induces both MMP-2 and -9 in ex vivo-
RA synovial explants. While both pro-MMP-2 and -9 forms were
induced, only active MMP-2 was induced by Pam3CSK4.
Finally, to examine if the Ang2/Tie2 pathway mediates TLR2
induced angiogenesis and invasion, HMVEC were cultured with
Pam3CSK4 in the presence or absence a specific anti-Tie2 antibody.
Minimal invasion was observed under basal condition or when
incubated with Anti-Tie2 or Anti-IgG alone. However we demon-
strated that Pam3CSK4- significantly induced EC invasion an effect
that was inhibited in the presence of anti-Tie2 (p,0.05) with no effect
observed with the isotype matched IgG control (Fig. 4). Furthermore
Pam3CSK4-induced tube formation (black arrows) was inhibited in
the presence of anti-Tie2 (white arrows) with no effect observed for
the isotype matched control (Fig. 5). Anti-Tie2 had no effect on
Pam3CSK4 induced ICAM-1 expression (data not shown). This data
confirms that Pam3CSK4 induced EC function is in part mediated
by the Ang2/Tie2 signalling pathway.
Discussion
Angiogenesis, cell adhesion and migrational processes play a
critical role in the pathogenesis of RA. TLR2 has been implicated
in the pathogenesis of RA, yet a role for TLR2 in angiogenesis and
EC activation has not been extensively studied. In this study we
demonstrate that TLR2 induces angiogenic tube formation and
Angiopoietin 2 expression which is a key growth factor involved in
new blood vessel formation and destabilisation. We demonstrate
increased ICAM-1 expression which is involved in leukocyte
migration in the inflamed joint. We demonstrate that TLR2
activation induces EC invasion and migration, in addition to
increased MMP-2 and -9 expression by RA synovial explants.
Finally, we show that TLR2-induced angiogenesis and invasion is
blocked by the presence of a specific anti-Tie2 monoclonal antibody.
The identification of pattern recognition TLRs in the RA joint
suggests they may play an important role in mediating
inflammatory responses in RA. Several studies have shown
TLR2 expression in RA synovial tissue and have shown that
TLR2 activation in RA synovial explants, RASFCs and
macrophages induces the MyD88/MAL pathway [6–10,19,24].
In animal models intra-articular injection of the TLR2 leads to
development of destructive arthritis in mice and TLR2/MyD88
knockout mice are protected from SWC induced joint inflamma-
tion [8]. Several potential TLR2 ligands have been implicated,
including Acute Serum Amyloid-A, Heat Shock protein/GP96,
Fibronectin fragments, Hyalauronidase oligosaccharides and
HMBG-1, all of which are highly expressed in RA synovial fluid
[25–29]. The existence of a ligand is further supported by studies
which show that conditioned media from RA synovial explants
can activate macrophages in a MyD88 and Mal dependent
manner [6].
Figure 3. TLR-2 activation induces EC invasion and migration and MMP-2 and 9 expression in RA synovial explants. (A)
Representative photomicrograph shows HMVEC invasion following Pam3CSK4 (1 mg/ml), stimulation. At 24 hours invading cells attached to lower
membrane were fixed (1% glutaraldehyde) and stained (0.1% crystal violet) (Mag640). (B) Representative bar graph quantifying HMVEC invasion.
(n = 4). *p,0.05 significantly different to control. (C) Representative photomicrograph showing cells repopulating the wound in response to
Pam3CSK4 (1 ug/ml). (D) Representative gel of MMP-2 and 9 activity by gelatine zymography in response to Pam3CSK4 in RA synovial explants (n = 3).
doi:10.1371/journal.pone.0023540.g003
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Angiogenesis is one of the earliest events in RA, facilitating
leukocyte extravasation, synovial proliferation and pannus forma-
tion [1–5]. Recruitment of inflammatory cells into the joint is
mediated by adhesion molecule/ligand pairs and chemokines [30].
Previous studies have demonstrated that TLR2 can induce one of
the main angiogenic growth factors VEGF, and the chemokine IL-
8, in fibroblast, chondrocytes, in corneal epithelial cells and THP-
1 macrophages [21,22,31]. Consistent with these studies a recent
report by Grote et al, demonstrated that the TLR2/6 agonist
macrophage-activating lipopeptide of 2 kDa (MALP-2), induced
angiogenic tube formation and leukocytes migration in vivo and in
vitro an effect mediated through GM-CSF pathways [32]. In this
study we demonstrate that TLR2 activation induces EC tube
formation and a key angiogenic growth factor Ang2. A close
relationship exists between the differential vascular morphology
within the inflammatory joint and the differential expression of
angiogenic growth factors such as VEGF, angiopoietins; Ang-1
and Ang-2, FGF-1, TGFb-1 and PDGF-1 [1,11–13,24,33].
Through its receptor Tie-2, Ang2 acts in the presence of abundant
VEGF on invading vascular sprouts by blocking the maturation
and stabilisation process, [15,16], these vessels remain in a ‘plastic’
state, in which they may become more responsive to a sprouting
signal provided by VEGF. Ang2 can also enhance chemotactic
migration of RASFC and can trigger EC permeability and recent
studies have demonstrated that in addition to its pro-angiogenic
properties, Ang2 can sensitise cells to TNFa stimulation,
suggesting it plays an important role in RA [34].
We demonstrated TLR2 activation-induced ICAM-1 expres-
sion on EC suggesting a potential mechanism whereby TLR2
promotes cell migration. This is consistent with studies using
mouse and human lung ECs where they demonstrate that TLR2
activation results in ICAM-1, VCAM-1 and chemokine expres-
sion, resulting in neutrophil trans-endothelial and leukocyte
recruitment [35,36]. In atherosclerosis models, TLR2 activation
of monocytes resulted in an increase in adhesive and migratory
capacity of cells [37]. Furthermore in primary synovial fibroblasts
PG activation induced ICAM-1, IL-6 and IL-8 [38]. These results
along with TLR2 induction of EC tube formation and
Angiopoietin 2 suggest that angiogenesis and leukocyte recruit-
ment to the joint may in part be mediated by TLR2.
Furthermore, we demonstrate that Pam3CSK4 significantly
induces cell invasion, cell migration and MMP-2 and -9 secreted
expression. Cell motility and ECM degradation are essential for
EC migration during angiogenesis and for the advancement of the
Figure 4. TLR2 induced EC invasion is inhibited by anti-Tie2. (A) Representative photomicrographs showing anti-Tie2 blocks Pam3CSK4
induced HMVEC invasion, with no effect observed for IgG control mAb. At 24 hours invading cells attached to lower membrane were fixed (1%
glutaraldehyde) and stained (0.1% crystal violet) (Mag640). (B) Representative bar graph quantifying HMVEC invasion. (n = 4). *p,0.05 significantly
different.
doi:10.1371/journal.pone.0023540.g004
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newly formed vessels through the synovial tissue [25,39–41]. The
invasion of blood vessels through the inflamed SM is facilitated by
induced expression of gelatin type matrix metalloproteinases
MMP-2 and -9. In vivo and in vitro studies have highlighted the
role of MMP-2 and 9 in angiogenesis and in the pathogenesis of
RA. MMP-2 and -9 are highly expressed in RA SM atheroscle-
rotic plaques and are upregulated during vascular injury [41–44],
Blockade of TLR2 signalling via MyD88, results in inhibition of
MMP-2 and -9 in a culture model of atherosclerosis [32], thus
further supporting the hypothesis that TLR2 blockade may
represent a potential therapeutic strategy for atherosclerosis,
autoimmune diseases and other vascular diseases.
Finally we demonstrated that TLR2 induced angiogenesis and
invasion were mediated through the Tie2 signalling pathway. The
effect of Tie2 blockade on TLR2 induced angiogenic mechanisms,
is most likely through TLR2 regulation of the Tie2 ligand Ang2, as
demonstrated in the RA synovial explant and endothelial cell
cultures. It is well established that modulation of the Tie2 receptor
by its ligand Ang2 is crucial for regulation of angiogenesis, blood
vessel maturation and vascular integrity [15,45–47], however this
is the first report to demonstrate that it mediates TLR2
downstream function. Several studies have demonstrated the
presence of Tie2 and its ligands in synovial tissue, synovial
fibroblast and RA osteoblasts [12,48,49]. In vitro and in vivo studies,
have shown TNFa induces Tie2, Ang1 and Ang2 expression in
RA synovial fibroblast [50–53]. Blocking Tie2 activation in a
collagen induced arthritis model inhibits arthritis-induced angiogen-
esis, RANKL expression leading to a reduction in bone erosion
suggesting Tie2 as a potential therapeutic target [52,53]. Ang2
deficient mice have an impaired ability to express cytokine-inducible
adhesion molecules [34]. Furthermore, Ang2 can also sensitize cells
to the actions of TNFa, where Ang2 promoted TNFa-induced
leukocyte rolling and adhesion molecule expression [34]. These
findings identify Tie2 as a key signalling pathway in inflammatory
arthritis and imply that interventions designed to target the upstream
triggers of the Tie2 pathway could be clinically beneficial.
In conclusion we have demonstrated that TLR-2 activation
plays a key role in several important mechanisms involved in
angiogenesis and advancement of blood vessel through the
inflamed synovial tissue effects that may in part be mediated by
the Ang2/Tie-2 signalling pathway. We have also shown the
relevance of TLR2 in both microvascular endothelial cells and RA
synovial cells in vitro and ex vivo. These findings provide evidence of
a common molecular link between TLR2 and the pathogenesis of
both vascular and joint inflammation and further highlight the
therapeutic potential of targeting TLR2 in the treatment of RA.
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Figure 5. TLR2 induced EC tube formation and wound repair are blocked by anti-Tie2. (A) Representative photomicrographs showing
anti-Tie2 blockade of TLR-2 induced angiogenesis, with effect observed for IgG control mAb (n= 3 experiments). Black arrows indicates an increase in
EC-EC connecting branches and tube formation in response to PAM3CSK4, white arrow indicates a decrease in the number of connecting branches in
the presence of an-Tie2. (B) Representative bar graph quantifying HMVEC tube formation *p,0.05 significantly different.
doi:10.1371/journal.pone.0023540.g005
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